Blood-based Liquid Biopsy Detects Lymph Node Metastasis in Colorectal Cancer Patients
|
By LabMedica International staff writers Posted on 04 May 2021 |

Image: Micrograph of a colorectal adenocarcinoma metastasis to a lymph node. The cancer (forming glands) is seen at the center-top. Adipose tissue is present on the upper right (Photo courtesy of Wikimedia Commons)
A recent paper described a novel, noninvasive liquid biopsy test for detection of lymph node metastasis in individuals with high-risk T1 colorectal cancer.
Local cancer in many parts of the body can cause lymph nodes to enlarge because of tumor cells that have metastasized into the node. Lymph node involvement is often a key factor in the diagnosis and treatment of cancer. As part of the investigations or workup for cancer, lymph nodes may be imaged or even surgically removed. Whether lymph nodes are affected will affect the staging of the cancer and overall treatment and prognosis.
Investigators at City of Hope (Duarte, CA, USA) had previously used surgically resected tissue specimens and endoscopic biopsies taken during colonoscopy to establish a panel of miRNAs and mRNAs for the identification of lymph node metastasis (LNM) in invasive submucosal colorectal cancers (T1 CRC). In the current study, they translated these tissue-based biomarkers into a noninvasive blood-based liquid biopsy assay.
The investigators analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from two clinical cohorts and matched FFPE (formalin-fixed-paraffin-embedded) samples. They performed RT-qPCR followed by logistic regression analysis to develop an integrated transcriptomic panel and establish a risk-stratification model, combined with clinical risk factors.
The liquid biopsy test was found to accurately identify lymph node metastasis with high sensitivity (83.3%) and specificity (76.2%). These results enabled the investigators to identify an optimized transcriptomic panel of four miRNAs (miR-181b, miR-193b, miR-195, miR-411) and five mRNAs (AMT, FOXA1, PIGR, MMP1, MMP9), which robustly identified patients with LNM. Application of this diagnostic model limited potential over-treatment to only 18% of all patients, which was dramatically superior to currently used models based on pathological features (92%).
"Since radical surgery dramatically reduces quality of life for patients, improving the success rate of identification of high-risk individuals with lymph node metastasis remains the challenge in T1 colorectal cancer diagnosis," said senior author Dr. Ajay Goel, chair of the department of molecular diagnostics and experimental therapeutics at City of Hope. "In the future, we hope to improve our confidence in identifying which individuals truly have lymph node metastasis via this novel biomarker-based liquid biopsy test for T1 colorectal cancer, in combination with clinical and pathological criteria. Obtaining results with more than 80% accuracy (sensitivity) in finding lymph node metastasis in the blood was a completely unexpected finding and is a complete game changer."
The blood-based liquid biopsy for detection of lymph node metastasis was described in the April 2, 2021, online edition of the journal Gastroenterology.
Related Links:
City of Hope
Local cancer in many parts of the body can cause lymph nodes to enlarge because of tumor cells that have metastasized into the node. Lymph node involvement is often a key factor in the diagnosis and treatment of cancer. As part of the investigations or workup for cancer, lymph nodes may be imaged or even surgically removed. Whether lymph nodes are affected will affect the staging of the cancer and overall treatment and prognosis.
Investigators at City of Hope (Duarte, CA, USA) had previously used surgically resected tissue specimens and endoscopic biopsies taken during colonoscopy to establish a panel of miRNAs and mRNAs for the identification of lymph node metastasis (LNM) in invasive submucosal colorectal cancers (T1 CRC). In the current study, they translated these tissue-based biomarkers into a noninvasive blood-based liquid biopsy assay.
The investigators analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from two clinical cohorts and matched FFPE (formalin-fixed-paraffin-embedded) samples. They performed RT-qPCR followed by logistic regression analysis to develop an integrated transcriptomic panel and establish a risk-stratification model, combined with clinical risk factors.
The liquid biopsy test was found to accurately identify lymph node metastasis with high sensitivity (83.3%) and specificity (76.2%). These results enabled the investigators to identify an optimized transcriptomic panel of four miRNAs (miR-181b, miR-193b, miR-195, miR-411) and five mRNAs (AMT, FOXA1, PIGR, MMP1, MMP9), which robustly identified patients with LNM. Application of this diagnostic model limited potential over-treatment to only 18% of all patients, which was dramatically superior to currently used models based on pathological features (92%).
"Since radical surgery dramatically reduces quality of life for patients, improving the success rate of identification of high-risk individuals with lymph node metastasis remains the challenge in T1 colorectal cancer diagnosis," said senior author Dr. Ajay Goel, chair of the department of molecular diagnostics and experimental therapeutics at City of Hope. "In the future, we hope to improve our confidence in identifying which individuals truly have lymph node metastasis via this novel biomarker-based liquid biopsy test for T1 colorectal cancer, in combination with clinical and pathological criteria. Obtaining results with more than 80% accuracy (sensitivity) in finding lymph node metastasis in the blood was a completely unexpected finding and is a complete game changer."
The blood-based liquid biopsy for detection of lymph node metastasis was described in the April 2, 2021, online edition of the journal Gastroenterology.
Related Links:
City of Hope
Latest Molecular Diagnostics News
- Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
- Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
- Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
- FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
- Whole Transcriptome Analysis Expands Understanding of Cancer Gene Fusions
- Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
- Genetic Test Improves Risk Prediction for Open-Angle Glaucoma
- Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
- Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment
- Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







